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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Describe the indications for surgical intervention in the management of patients with hydatidiform moles and
malignant GTN in order to choose patients most likely to benefit from these interventions.
2. Discuss the use of radiation in the management of patients with malignant GTN and consider its use as an adjunct
to chemotherapy or surgery.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
The primary management of hydatidiform moles re-
mains surgical evacuation followed by human chorionic
gonadotropin level monitoring. Although suction dila-
tation and evacuation is the most frequent technique for
molar evacuation, hysterectomy is a viable option in
older patients who do not wish to preserve fertility. De-
spite advances in chemotherapy regimens for treating
malignant gestational trophoblastic neoplasia, hyster-
ectomy and other extirpative procedures continue to
play a role in the management of patients with both low-
risk and high-risk gestational trophoblastic neoplasia.
Primary hysterectomy can reduce the amount of che-
motherapy required to treat low-risk disease, whereas
surgical resections, including hysterectomy, pulmonary
resections, and other extirpative procedures, can be in-
valuable for treating highly selected patients with per-
sistent, drug-resistant disease. Radiation therapy is also
often incorporated into the multimodality therapy of
patients with high-risk metastatic disease. This review
discusses the indications for and the role of surgical in-
terventions during the management of women with
hydatidiform moles and malignant gestational
trophoblastic neoplasia and reviews the use of radiation
therapy in the treatment of women with malignant ges-
tational trophoblastic neoplasia. The Oncologist 2010;15:
593–600
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INTRODUCTION
Hydatidiform moles and malignant gestational trophoblas-
tic neoplasia (GTN) are recognized as relatively uncom-
mon, but potentially devastating, diseases occurring in
women of reproductive age. Primary management of hyda-
tidiform moles includes surgical evacuation coupled with
close monitoring of serial human chorionic gonadotropin
(hCG) values. In patients with malignant GTN, surgery was
initially recognized as effective only in the treatment of a
few women with nonmetastatic choriocarcinoma or post-
molar GTN. Malignant GTN was usually a rapidly pro-
gressing lethal malignancy until Li et al. [1] reported the
first complete and sustained remission using chemotherapy
in a patient with metastatic choriocarcinoma who was suc-
cessfully treated with methotrexate. Although surgery has
assumed a lesser role in the management of malignant
GTN, selected surgical procedures remain important in the
treatment of individual patients. Radiation therapy has been
used to control disease in the central nervous system (CNS),
liver, and rarely, at other sites.
EVACUATION OF HYDATIDIFORM MOLE
Dilatation and suction evacuation (D&E) is the preferred
technique of molar evacuation. Various other methods in-
clude medical induction of labor, hysterotomy, and hyster-
ectomy.
INDUCTION OF LABOR
Induction of labor for molar pregnancy termination can be
achieved by the use of prostaglandins with or without the
addition of oxytocin. Oxytocin is used if the pregnancy is
14 weeks’ gestation because of the lower amount of oxy-
tocin receptors before this gestational age [2, 3]. Laminaria
may be used to assist in cervical ripening. There has been
reluctance to recommend labor induction for molar evacu-
ation because of the theoretical risk for trophoblastic depor-
tation and embolization during uterine contractions that
might result in distant metastasis.
Tidy and associates retrospectively compared different
methods of molar evacuation, reporting that medical induc-
tion was associated with higher rates of chemotherapy for
postmolar GTN [4]. They attributed this effect to higher
rates of incomplete evacuation than with suction D&E. Ad-
ditionally, Schlaerth et al. [5] reported that the rates of sig-
nificant hemorrhage and incomplete evacuation were
higher after induction of labor than after D&E. Further-
more, all but one of their patients ultimately required suc-
tion D&E after induction of labor to complete the
evacuation [6]. However, when Flam et al. [7] reviewed the
prognostic factors influencing postmolar GTN, they re-
ported that uterine size was more important than the mode
of molar evacuation.
ABDOMINAL HYSTEROTOMY
Abdominal hysterotomy was used in the past when suction
D&E techniques were not widely available. Acute morbid-
ity, including operative blood loss, is greater than with suc-
tion D&E. The vertical myometrial incision used to
evacuate the mole usually results in operative delivery for
subsequent pregnancies. This is an important consideration
because the majority of women with hydatidiform moles
are in the prime reproductive age group [6]. In a report of
347 patients with hydatidiform moles, Curry et al. [8] found
that only 18 (64%) of the 24 patients with evacuation by
hysterotomy entered spontaneous remission, compared
with 243 (81%) of the 299 who underwent D&E.
Because of the concerns for greater morbidity and a
higher incidence of postmolar GTN, induction of labor and
abdominal hysterotomy are rarely used for the primary
evacuation of hydatidiform moles [6].
SUCTION D&E
Suction D&E is a safe, rapid, and effective method for evac-
uating hydatidiform moles [6]. Pre-evacuation insertion of
cervical laminaria may facilitate cervical dilatation in a
medically stable patient. The majority of the molar tissue is
removed by simply rotating the suction cannula and allow-
ing the uterus to involute during evacuation of the uterine
contents. The surgeon can assist in uterine involution by
gentle uterine massage during evacuation, which also al-
lows assessment of uterine size during the curettage. The
use of a bedside ultrasound unit at the time of suction D&E
may further ensure complete evacuation of the uterine con-
tents.
The use of ergotamine in the form of methergine (0.2
mg every 2–4 hours) following evacuation is encouraged.
Routine second and third evacuations were often performed
in the past, but are discouraged because they do not appear
to decrease the risk for postmolar GTN [9] and may result in
perforation or uterine senechiae. Anti-D immunoglobulin
should be given to Rh patients because Rh D factor is ex-
pressed in the trophoblast.
In the U.S., sharp curettage is often performed with a
large curette to ensure complete uterine evacuation, and this
specimen is submitted for separate histological analysis.
Rice et al. [10] concluded that the diagnosis of invasive
mole or choriocarcinoma is rarely made from the sharp cu-
rettings. In their review of pathologic specimens, only one
pathologic feature, fibrinoid deposits, identified in sharp
curettings was associated with the incidence of persistent
GTN. Although 12 of the 25 patients who attained remis-
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sion without chemotherapy had fibrinoid deposits in the
sharp curettage specimen, they were identified in only one
of the eight patients who developed persistent GTN.
Complication rates after suction D&E are higher in uteri
of 16 weeks’ gestation, including hemorrhage, perfora-
tion, and pulmonary complications [11, 12]. Patients with a
markedly enlarged uterus should have large-bore i.v. infu-
sion catheters and blood available for transfusion. Central
hemodynamic monitoring and provision for immediate lap-
arotomy or laparoscopy during the procedure should also be
available [6].
Uterine perforation is a relatively rare complication
when suction D&E is used for molar evacuation [6]. Rarely,
perforation occurs in a region of deep myometrial penetra-
tion by invasive mole or there is active bleeding at the per-
foration site. Surgical management in these cases should be
individualized on the basis of the site and extent of perfo-
ration. Repair or resection of the perforation site is usually
attempted, but hysterectomy is often required in this setting
[6].
In patients who desire retention of fertility and are faced
with significant continuous vaginal bleeding after suction
D&E, hemorrhage can be controlled by balloon tamponade
such as with the Bakri balloon used in postpartum hemor-
rhages, as reported by Kolomeyevskaya et al. [13]. Uterine
artery embolization is another technique that has been used
in cases of severe hemorrhage to avoid hysterectomy after
excluding uterine perforation as a cause of bleeding.
HYSTERECTOMY
For women who have completed their families and have
risk factors for postmolar GTN, hysterectomy offers the ad-
vantage of simultaneous evacuation and sterilization [6].
Because malignant sequelae are more prone to occur in
older age groups—37.5% of patients aged 50 years ver-
sus 27.5% of patients aged 40–49 years versus 13.9% of
patients aged 15 years—after molar evacuation [14], hys-
terectomy plays a crucial role in the management of these
patients and offers a lower risk for malignant sequelae than
with suction D&E [15]. Hysterectomy decreases the overall
risk for postmolar GTN to approximately 3.5% from the an-
ticipated 20% following suction D&E [8].
Because most women with hydatidiform moles are aged
40 years, the adnexa should not be removed unless the pa-
tient has obvious adnexal metastases, is perimenopausal, or
has complications related to theca lutein cysts [6]. All pa-
tients should be chemically monitored after hysterectomy
because it does not completely eliminate the potential for
postmolar GTN [8, 15].
THECA LUTEIN CYSTS
Theca lutein ovarian cysts usually are present at the time of
presentation in about 25% of patients [16], but can develop
after molar evacuation. They are caused by elevated hCG
levels [17]. Other signs of ovarian hyperstimulation, such
as pleural effusion and ascites, have been documented. The
resolution of theca lutein cysts lags behind the drop in hCG
values. They may take several months to resolve, but re-
quire surgical intervention in only 3% of cases for rupture
or torsion [16]. If these are recognized at the time of surgi-
cal exploration, aspiration of prominent cysts can be per-
formed.
SURGERY INCORPORATED IN THE MANAGEMENT OF
MALIGNANT GTN
The emergence of effective chemotherapy has lessened the
importance of surgery for patients with malignant GTN.
Hysterectomy may be incorporated into the primary or sec-
ondary management of women with GTN [6, 18, 19]. Pa-
tients with high-risk GTN often require surgery to address
disease complications [6, 19].
Surgical procedures to extirpate sites of disease are of-
ten performed during a course of chemotherapy to mini-
mize the possibility of inducing metastases by surgical
manipulation of tissues.
PRETHERAPY D&E
Patients who develop postmolar GTN frequently present
with vaginal bleeding and uterine enlargement [6]. The ef-
ficacy of a second therapeutic D&E to remove additional
trophoblastic tissue and allow spontaneous regression has
never been prospectively evaluated. However, several ret-
rospective studies suggest that routine performance of a re-
peat D&E is not likely to benefit the majority of patients
with postmolar GTN [20–22].
Only 20% of 37 patients reported by Schlaerth and col-
leagues [21] with nonmetastatic GTN had a sustained drop
in hCG levels and entered into spontaneous remission after
the second procedure. Likewise, others have observed that a
second D&E affects management in 10% of patients after
primary evacuation of a hydatidiform mole by directly pro-
ducing remission or providing histological evidence of ma-
lignant GTN [20–22]. In contrast, Pezeshki and colleagues
evaluated the results of a second uterine evacuation for a
presumptive diagnosis of GTN during follow-up in 544 pa-
tients after molar evacuation [23]. Among the 282 patients
with a second evacuation performed for rising or persistent
hCG values, only 40% required chemotherapy. Chemother-
apy was more likely when the urinary hCG level was
1,500 IU/l at the time of the secondary evacuation, or if
there was histologic evidence of GTN in the curettings.
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A second D&E might theoretically reduce the amount of
chemotherapy needed to produce remission, if performed
immediately prior to treatment, by debulking the intrauter-
ine tumor burden. In a study by van Trommel et al. [22], a
median of six cycles of chemotherapy was required in the
control group of 209 patients who did not undergo a second
D&E, compared with five courses in patients receiving a
second procedure (p  .036). In a retrospective review of
150 patients treated with methotrexate for low-risk postmo-
lar GTN, however, Growdon and associates [24] found no
association between a second D&E and the number of
methotrexate courses or the need for alternative chemother-
apy regimens.
Repeat curettage may carry a higher risk for complica-
tions than primary D&E for molar evacuation. Schlaerth
and associates reported an 8.1% incidence of uterine perfo-
ration during the secondary D&E among 37 patients who
underwent a secondary curettage during the course of treat-
ment for postmolar GTN [21]. Uterine perforations or
blood loss 1,000 ml occurred in 4.8% of the 85 patients in
the series reported by van Trommel et al. [22], whereas no
significant acute complications were reported by Pezeshki
et al. [23]. No study to date has investigated the long-term
incidence of uterine senechiae after a second D&E.
Most investigators are reluctant to recommend routine
pretherapy D&E. However, a few patients require a second
D&E before or during chemotherapy because of hemor-
rhage with anemia or because of infected products of con-
ception.
HYSTERECTOMY FOR MALIGNANT GTN
The majority of women with malignant GTN can be cured
with chemotherapy alone. Hysterectomy, however, contin-
ues to play a role in the management of women with malig-
nant GTN.
A 100% sustained remission rate was reported for 194
patients treated for nonmetastatic or low-risk metastatic
GTN by Hammond et al. [19]. Of these, 162 wished to pre-
serve fertility and 89% were able to avoid hysterectomy.
All 32 women treated with primary hysterectomy combined
with single-agent chemotherapy regimens entered sus-
tained remission. When compared with similar patients
who had low-risk disease and were treated with chemother-
apy alone, patients receiving primary hysterectomy had a
shorter duration and lower total dose of chemotherapy,
equivalent to one cycle of chemotherapy [19]. In another
retrospective study, the total dose of etoposide used for
low-risk GTN patients was lower among those with non-
metastatic disease treated with adjuvant hysterectomy than
among those treated with chemotherapy alone, again
roughly equivalent to a single cycle of chemotherapy. This
effect was not observed among the patients with low-risk
metastatic disease [25]. Therefore, primary hysterectomy is
a reasonable adjunct to chemotherapy for patients with low-
risk GTN who do not desire to preserve their childbearing
capacity [11].
Additionally, hysterectomy can be employed in patients
with nonmetastatic or low-risk metastatic GTN who be-
come resistant to primary chemotherapy, in order to
achieve remission without requiring multiagent chemother-
apy. As reported by Hammond et al. [19], 13 of 122 patients
with nonmetastatic GTN and five of 40 patients with low-
risk metastatic GTN who demonstrated failure of remission
after chemotherapy were placed in sustained remission af-
ter secondary or tertiary hysterectomy. Primary or second-
ary hysterectomy, however, was not effective in reducing
chemotherapy requirements or improving cure rates for
women with high-risk metastatic GTN [19]. This likely re-
flects a greater extrauterine disease burden in these women.
Salvage hysterectomy is an option in producing remis-
sion in most patients with chemoresistant nonmetastatic or
low-risk metastatic disease [19, 26, 27]. Salvage hysterec-
tomy may be integrated into the treatment of selected pa-
tients with high-risk metastatic GTN who have a small
extrauterine tumor burden. Patients with recurrent GTN of-
ten present with limited extrauterine dissemination and may
benefit from salvage hysterectomy [28].
Hysterectomy for GTN treatment can prove very diffi-
cult. The uterine vasculature may be very prominent, and
enlargement of the uterine venous plexus may lead to hem-
orrhage during ureteric dissection, particularly in cases in
which the tumor has spread beyond the uterus into the
parametrium. Temporary ligation of the hypogastric arter-
ies may be helpful in reducing intraoperative hemorrhage
[29].
Emergency hysterectomies have been reported in cases
of intra-abdominal bleeding or severe vaginal bleeding
[30]. In a series of 18 total abdominal hysterectomies, four
were performed emergently as a result of uterine perfora-
tion resulting in massive hemoperitoneum [31]. Addition-
ally, it is important to emphasize the need for a detailed
intraoperative examination after completion of the hyster-
ectomy to exclude or identify any metastatic lesions.
In contrast to gestational choriocarcinoma or postmolar
GTN, hysterectomy plays an essential role in the manage-
ment of placental site trophoblastic tumor (PSTT) because
it is much more resistant to methotrexate and dactinomycin
chemotherapy. Most patients present with nonmetastatic
PSTT. Hysterectomy alone is curative in approximately
two thirds of patients [32, 33]. Conversely, hysterectomy is
not as beneficial in the management of PSTT patients with
widespread metastases.
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CONSERVATIVE MYOMETRIAL RESECTION
Conservative myometrial resection combined with uterine
reconstruction might be considered in highly selected pa-
tients with nonmetastatic GTN who wish to avoid hysterec-
tomy [34–36]. Kanazawa et al. [34] evaluated 22 patients
with local myometrial resection of invasive moles. All pa-
tients had lesions localized in the myometrium, defined by
pelvic angiography, ultrasound, and computerized tomog-
raphy techniques. Seven patients required chemotherapy
after surgery. They observed that the reproductive perfor-
mance of patients undergoing myometrial resection was
similar to that of patients treated with chemotherapy alone.
Any patient considered for this procedure should be care-
fully evaluated for systemic metastases, and the uterine le-
sion should be localized by imaging and hysteroscopy.
Intraoperative frozen sections should be used to assess sur-
gical margins. Their indications for selecting patients for
conservative myometrial resections were: (a) urinary hCG
titers 10,000 IU/day, (b) no evidence of pulmonary in-
volvement, and (c) metastases in the lungs, controlled by che-
motherapy prior to the operation. They reported that
postsurgical chemotherapy might be avoided or reduced if
these criteria were fulfilled [34]. An exception to these guide-
lines is uterine perforation and/or marked uterine hemorrhage
resulting from myometrial invasion of a molar trophoblast, for
which emergent focal resection may be indicated.
During a hysterectomy or myometrial resection for any
of the above indications, ovarian removal is not usually re-
quired, because GTN rarely metastasizes to the ovaries and
these tumors are not hormonally influenced [6].
CONSERVATIVE MANAGEMENT OF
UTERINE RUPTURE
Estrella and Soriano-Estrella [37] reported on two patients
with low-risk GTN managed by primary repair of uterine
rupture and subsequent chemotherapy, with a documented
complete response in one patient, whereas the other was
lost to follow-up.
PULMONARY RESECTION
The most frequently employed surgical procedure for extir-
pation of extrauterine metastases of GTN is thoracotomy
with pulmonary wedge resection. Although this can safely
be performed in conjunction with chemotherapy, it is not
necessary to resect lung metastases in the majority of pa-
tients [6]. Resection of pulmonary nodules in highly se-
lected patients with drug-resistant disease may successfully
induce remission after excluding active disease elsewhere
[6]. Highly selected patients will require more than one pul-
monary resection during the course of treatment in order to
achieve a durable remission [26].
Tomoda et al. [38] proposed the following criteria for
successful pulmonary resection: (a) the patient must be sur-
gically fit, (b) the primary malignancy must be controlled
(the uterus must have already been resected or there must be
no radiographic evidence of tumor in the uterine cavity), (c)
there must be no evidence of widely disseminated meta-
static disease elsewhere in the body, (d) the radiologic evi-
dence of pulmonary metastasis must be limited to one lung,
and (e) the urinary hCG value must be 1,000 mIU/ml. Re-
mission was achieved in 14 of their 15 patients who met the
above criteria [38].
CRANIOTOMY
Brain metastases occur in 9.3%–21.4% of patients with
metastatic GTN [39, 40] and are associated with a worse
prognosis than with vaginal or pulmonary metastases [6].
The key factors for a successful outcome in managing these
patients are early diagnosis and aggressive therapy. These
lesions tend to be highly vascular and have a tendency for
central necrosis and hemorrhage. Early deaths are caused
by acute hemorrhage, with acute neurological deterioration
very early in the course of treatment [39, 40]. Any woman
of reproductive age diagnosed with brain metastasis or ce-
rebral hemorrhage should be screened for GTN with a se-
rum hCG test. Tissue confirmation is not necessary for the
diagnosis of brain metastasis [6]. In the U.S., brain irradia-
tion has usually been integrated into the treatment of brain
metastasis in an attempt to prevent hemorrhage and neuro-
logical deterioration [26, 41]. Craniotomy has usually been
used only to prevent acute deterioration [19].
Ishizuka et al. [40] concluded, from autopsy studies,
that surgical decompression should be performed in any pa-
tient with signs or symptoms of increased intracranial pres-
sure, followed closely by multiagent chemotherapy.
Furthermore, Rustin and associates [42] recommended
early craniotomy with excision of isolated lesions com-
bined with high-dose systemic and intrathecal chemother-
apy to treat patients with brain metastases, reporting a 72%
sustained complete remission rate. Others have confirmed
the feasibility of this approach [43].
Evans et al. [39] demonstrated a similar rate of sustained
complete remission in patients who presented with CNS
metastasis and who were treated with primary therapy using
multiagent chemotherapy consisting of methotrexate, acti-
nomycin D, and chlorambucil or etoposide-based regimens,
given with concurrent whole-brain irradiation at a dose of
3,000 cGy in 10 fractions. Intrathecal methotrexate was not
used in that series [39]. These reports underscore the value of
multiagent chemotherapy and multimodality therapy in the
management of metastatic GTN to the brain, using different
approaches to avoid early mortality from the CNS lesions.
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In patients with drug-resistant brain lesions, it is of vital
importance to exclude active disease elsewhere prior to at-
tempting surgical resection because craniotomy in these in-
stances is rarely effective [6].
SURGICAL MANAGEMENT OF RENAL METASTASES
The incidence of renal metastases is 1%–14% in GTN pa-
tients [44]. Soper and associates described eight patients
with high-risk clinical factors treated for renal metastasis
of GTN, all of whom had pulmonary metastasis [44].
Four patients additionally had CNS disease. Combination
chemotherapy, including methotrexate, dactinomycin, and
chlorambucil, was given to all patients. Five received eto-
poside-containing regimens as salvage therapy. None re-
ceived renal irradiation and five underwent nephrectomies.
Three patients in that series survived. All had limited met-
astatic disease elsewhere [44]. Nephrectomy should be con-
sidered only if there is unilateral involvement and limited
disease involving the lungs, but may not contribute to sur-
vival in patients with extensive systemic disease [44, 45].
TREATMENT OF METASTATIC VAGINAL DISEASE
Vaginal metastases of malignant GTN are highly vascular.
Biopsy or resection of these lesions should not be under-
taken unless they are the only sites of chemoresistant dis-
ease. Packing or angiographic embolization are usually
used in an attempt to acutely control bleeding during initi-
ation of therapy [6].
SURGICAL MANAGEMENT OF LIVER METASTASES
Most patients with metastatic liver disease should be man-
aged initially with multiagent chemotherapy. Only rarely
will resection of isolated liver metastases be feasible for
treatment of drug-resistant disease because most patients
will have other sites of active disease, or disseminated in-
volvement of the liver [6].
INVOLVEMENT OF OTHER
INTRA-ABDOMINAL ORGANS
If chemotherapy has not been effective in controlling met-
astatic sites involving other abdominal or pelvic organs,
surgical resection or the application of other procedures is
dependent on the organ and the symptoms associated with
its involvement. Rarely, intestinal resection is required in
cases of gastrointestinal bleeding [19, 46].
The probability of achieving a complete response fol-
lowing various salvage surgical procedures in patients with
chemorefractory GTN was evaluated by Lehman and asso-
ciates [26] in a series of 33 patients. The patients who were
successfully salvaged: (a) had one preoperative disease site,
(b) underwent salvage surgery within 1 year from the time
of initial diagnosis, (c) had pathological specimens with
histologic findings other than choriocarcinoma, and (d) had
a total World Health Organization score 8.
Conversely, Feng et al. [47] evaluated 61 patients with
chemoresistant GTN who underwent various salvage surgi-
cal procedures in the course of their management for pre-
dictive factors of poor response to surgical management.
Patients with PSTT were excluded. The clinical factors
predicating failure of salvage surgery were: (a) age 35
years, (B) hCG value 10 IU/L, (c) antecedent nonmolar
pregnancy, and (d) metastasis outside the lungs.
ANCILLARY PROCEDURES
Selective angiographic localization and embolization tech-
niques have been used to conservatively manage hemor-
rhage from active sites of metastatic GTN and to treat
intrauterine arteriovenous malformations that can occa-
sionally develop after treatment of GTN [4]. Grumbine et
al. [48] reported prophylactic placement of a catheter in the
hepatic artery for balloon occlusion or embolization in the
event of rupture in a patient with liver metastases of GTN.
Lang [49] used selective catheter placement for chemoem-
bolization in three patients with liver metastases and two
patients with pelvic tumors from GTN. All had chemoresis-
tant GTN and relatively localized persistent tumors. Two of
the patients with liver metastases achieved long-term re-
missions, with minimal hematological toxicity. Recently
Soper et al. [43] reported a long-term survivor with exten-
sive liver, lung, and brain metastasis from GTN who re-
quired embolization of multiple bleeding liver lesions to
allow stabilization during initial therapy. A rare case of pri-
mary choriocarcinoma of the cervix was also recently de-
scribed, presenting with massive cervical bleeding that was
successfully controlled with selective uterine artery embo-
lization [50].
RADIATION THERAPY FOR MALIGNANT GTN
Radiation has a limited but vital role in the management of
patients with malignant GTN, frequently used to treat pa-
tients with brain or liver metastases in an effort to minimize
hemorrhagic complications at these sites. Patients who de-
velop brain metastases while on treatment or relapse in the
brain after an initial complete remission represent a group
of patients with a worse prognosis than those who present
with brain metastases before treatment [39, 51–54]. Whole-
brain radiation is usually administered at 2,000–4,000 cGy
in 10–20 equal fractions that are given concurrently with
combination chemotherapy, with reduced-field boosts
given in selected patients. The combination of chemother-
apy and radiation is both hemostatic and tumoricidal [55].
Survival rates of 50%–75% were reported in a series of pa-
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tients who initially presented with brain metastases and re-
ceived combined chemoradiation [6].
An alternative approach using high-dose systemic combi-
nation chemotherapy and early neurosurgical intervention
yields results similar to those with the concurrent chemoradia-
tion approach, as described previously [42, 43]. Concerns
about neurocognitive toxicity from concurrent moderate- to
high-dose methotrexate and whole-brain radiation therapy
have led to adaptation of the above approach to the treatment
of CNS metastases at some centers in the U.S. [43].
Barnard et al. [56] reported on 15 patients with liver me-
tastasis receiving whole-liver irradiation concurrently with
chemotherapy. Only two (13%) patients survived. In an ef-
fort to limit radiation-induced hepatitis, the recommended
dose of whole-liver radiation is 2,000 cGy administered
over 2 weeks [54, 56]. However, in a series reported by
Bakri et al. [57], none of the eight patients treated with
methotrexate– dactinomycin– cyclophosphamide com-
bined with whole-liver radiation survived, compared with
survival in five of the eight patients treated with etoposide-
based combination regimens given without radiation.
Radiation of the kidneys is unlikely to achieve signifi-
cant disease control for bilateral renal metastases given the
low radiation tolerance of the kidneys [44]. Unilateral renal
metastasis might be treated with radiotherapy, but the com-
bination of chemotherapy and irradiation was not success-
ful in a patient reported by Mazur et al. [58].
CONCLUSION
Despite advances in chemotherapy for GTN, surgical pro-
cedures and radiation therapy continue to play significant
roles in the management of women with hydatidiform
moles and malignant GTN. The integration of multimodal-
ity treatment, especially in patients with high-risk disease,
requires physicians with experience in the treatment of
these diseases in order to coordinate all aspects of therapy.
Cure rates of 75%–84% for patients with high-risk disease
are reported from centers that specialize in the treatment of
women with this malignancy.
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